The Year’s Two Largest Conjugate Deals Were Not ADCs, and Not Cancer Drugs
Buyers stopped paying for conjugate drugs and started paying for conjugate chemistry. The year’s two biggest cheques bought neither an ADC nor a cancer drug.
DealPulse Signal
The Beats
Analysis
The Briefs
The Year’s Two Largest Conjugate Deals Were Not ADCs, and Not Cancer Drugs
ITM’s Complete Response Letter Names No Clinical Concern. It Names a Third-Party Facility.
DuPont Spun Chemours Off in 2015. Eleven Years On, Both Are Named in the Same Order.
Corline’s Whole Pulsed Field Upside Depends on One Customer’s Regulatory Calendar
MoonLake Says IZAR-1 Met Every Endpoint and Will Not Show You the Placebo Arm